BioAtla, Inc. (BCAB)

In August 2025, BioAtla provided a corporate update and reported Q2 2025 financial results, showing decreased R&D expenses and an improved net loss, but reduced cash reserves. In November 2025, BioAtla announced Q3 2025 financial results, reporting an increased net loss, decreased R&D and G&A expenses, received a milestone payment from Context Therapeutics, presented data for Mecbotamab Vedotin, and secured flexible financing. In December 2025, BioAtla and GATC Health announced a Special Purpose Vehicle transaction to advance Ozuriftamab Vedotin. In February 2026, BioAtla received a non-compliance letter from Nasdaq due to not meeting the minimum bid price requirement, and the stock price experienced a significant decline.

BioAtla, Inc.'s products are not yet commercialized, so traditional demand seasonality does not apply; investor interest and clinical pipeline progress primarily drive demand.

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancers, utilizing its Conditionally Active Biologics (CAB) platform to target the tumor microenvironment. Key product candidates include Ozuriftamab Vedotin (Oz-V / BA3021) for Oropharyngeal Squamous Cell Carcinoma, Mecbotamab Vedotin (Mec-V / BA3011) for soft tissue sarcomas, BA3182 for refractory metastatic adenocarcinoma, Evalstotug (BA3071) for melanoma, renal cell carcinoma, colorectal cancer, and NSCLC and CAB-Nectin4-TCE (BA3361) which is licensed to Context Therapeutics.

BioAtla, Inc. is headquartered in San Diego, California, and maintains operations in Beijing, China, through a contractual relationship with BioDuro-Sundia.

BioAtla's brand reputation has been influenced by positive clinical advancements and financial challenges. Positive impacts include promising clinical data for lead product candidates, FDA Fast Track Designation for Oz-V, and strategic financing transactions. Negative impacts include low cash reserves, increased net losses, workforce reduction, and a non-compliance letter from Nasdaq regarding the minimum bid price requirement.

BioAtla, Inc.'s ownership includes institutional, insider, and retail investors. Institutional owners hold a total of 13,854,936 shares, with major holders including Acorn Capital Advisors LLC and Vanguard Group Inc. Insiders collectively hold 35.36% of the company, with Carolyn Anderson Short being the largest individual shareholder and Jay M. Short directly owning 5.4% of the company's shares.